Roche Holding : 2023 results slightly below expectations and uninspiring 2024 outlook
>2023 results a shade below expectations - 2023 results came in 1% below the consensus (Visible Alpha), showing growth of 1% at constant exchange rates (-7% CHF). The pharma division (-1% vs consensus) posted growth of 6% at CER (-2% CHF) driven by Vabysmo (+4% vs consensus) which is the largest contributor to growth (2023 sales: CHF 2,357m vs 2022: CHF 591m). The performances of the flagship products were somewhat disappointing: Ocrevus (+6%, -1% vs cons., Perjeta (...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.